BioCentury
ARTICLE | Company News

J&J, Akebia deal

February 24, 2017 2:17 AM UTC

Johnson & Johnson’s Janssen Pharmaceutica N.V. company granted Akebia exclusive, worldwide rights to develop and commercialize a portfolio of preclinical inflammatory bowel disease small molecules tha...